The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Renal cell carcinoma (RCC) is one of the most common tumours of the urinary system, and is insidious and not susceptible to chemoradiotherapy. As the most common subtype of RCC (70–80% of cases), clear cell renal cell carcinoma (ccRCC) is characterized by the loss of von Hippel–Lindau and the accumulation of robust lipid and glycogen. For advanced RCC, molecular‐targeted drugs, tyrosine kinase inhibitors (TKIs) and the immune checkpoint inhibitors (ICIs) have been increasingly recommended and investigated. Due to the existence of a highly dynamic, adaptive and heterogeneous tumour microenvironment (TME), and due to the glucose and lipid metabolism in RCC, this cancer may be accompanied by various types of resistance to TKIs and ICIs. With the increased production of lactate, nitric oxide, and other new by‐products of metabolism, novel findings of the TME and key metabolic enzymes drived by HIF and other factors have been increasingly clarified in RCC carcinogenesis and therapy. However, there are few summaries of the TME and tumour metabolism for RCC progression and therapy. Here, we summarize and discuss the relationship of the important implicated characteristics of the TME as well as metabolic molecules and RCC carcinogenesis to provide prospects for future treatment strategies to overcome TME‐related resistance in RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846 · cited 1×
“Inhibition of LOX activity was shown to significantly suppress CCL2 and IL‐10 production by RCC TAMs and provided a new strategy for LOX‐dependent arachidonic acid metabolism in the TME to block immune escape and cancer‐related inflammation in RCC patients (Daurkin et al., 2011).”
BackgroundPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · cited 2×
“With the emergence of ICIs, the combination of TKIs (e.g., axitinib) and ICIs (e.g., pembrolizumab) has also been increasingly investigated (Rini et al., 2019).”
BackgroundReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 2×
“oxygen and glutamine metabolism in producing AcCoA and supporting lipid synthesis was identified (Metallo et al., 2011).”
BackgroundZhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249 · cited 10×
“In conclusion, accumulating evidence has shown the important im- plicated characteristics of the TME as well as metabolic molecules in RCC carcinogenesis and RCC therapy resistance, and that additional therapies targeting the TME and aberrant metabolic pathways and their combination with ICIs or TKIs in ccRCC will soo…”
BackgroundInfluentialHypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976
Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09277-9 · Cited by 887
Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30413-9 · Cited by 775 · cited 1×
“…patients with previously untreated advanced RCC, combination ICI therapy that have different targets with ipilimumab (anti‐CTLA‐4) plus nivolumab (anti‐PD‐1) has demonstrated superiority over sunitinib monotherapy in terms of overall survival (OS) and objective response rates (Motzer et al., 2019).”
BackgroundTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Cited by
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Zhou, M., Yuan, M., Zhang, M., Lei, C., Aras, O., Zhang, X., & An, F. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113825 · Cited by 92
Kim, N. Y., Jung, Y. Y., Yang, M. H., Chinnathambi, A., Govindasamy, C., Narula, A. S., Namjoshi, O. A., Blough, B. E., & Ahn, K. S. (2022) · Biochimie · doi:10.1016/j.biochi.2022.05.018 · Cited by 24
The role of hyaluronan in renal cell carcinoma
Jin, C., & Zong, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127828 · Cited by 17
Huang, H., Cai, Y., Hong, X., Gao, W., Tang, J., Zhang, S., & Xu, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.948734 · Cited by 6
Metadata
- Authors
- Lai, Y., Tang, F., Huang, Y., He, C., Chen, C., Zhao, J., Wu, W., & He, Z.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2020-08-11
- Volume
- 236
- Issue
- 3
- Pages
- 1616-1627
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W3048711468
- Cited by
- 139
- References
- 22
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. https://app.cochat.ai/papers/10.1002/jcp.29969
- The paper
- Lai, Y., Tang, F., Huang, Y., He, C., Chen, C., Zhao, J., Wu, W., & He, Z. (2021). The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.29969
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.